Results 161 to 170 of about 6,747 (225)

H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition. [PDF]

Neuro Oncol
Guo Y, Li Z, Parsels LA, Wang Z, Parsels JD, Dalvi A, The S, Hu N, Valvo VM, Doherty R, Peterson E, Wang X, Venkataraman S, Agnihotri S, Venneti S, Wahl DR, Green MD, Lawrence TS, Koschmann C, Morgan MA, Zhang Q.   +20 more
europepmc   +1 more source

Clinical Pharmacogenetic Testing and Application: 2024 Updated Guidelines by the Korean Society for Laboratory Medicine. [PDF]

Ann Lab Med
Rim JH, Kim YG, Kim S, Choi R, Lee JS, Park S, Lee W, Song EY, Lee SY, Chun S, Pharmacogenetics Guideline Task-Force Team of the Korean Society for Laboratory Medicine.   +10 more
europepmc   +1 more source

Scalable data harmonization for single-cell image-based profiling with CytoTable. [PDF]

Patterns (N Y)
Bunten D, Tomkinson J, Serrano E, Lippincott MJ, Brewer KI, Rubinetti V, Alquaddoomi F, Way GP.   +7 more
europepmc   +1 more source

Mapping multimodal phenotypes to perturbations in cells and tissue with CRISPRmap. [PDF]

Nat Biotechnol
Gu J, Iyer A, Wesley B, Taglialatela A, Leuzzi G, Hangai S, Decker A, Gu R, Klickstein N, Shuai Y, Jankovic K, Parker-Burns L, Jin Y, Zhang JY, Hong J, Niu X, Costa JA, Pezet MG, Chou J, Chen C', Paiva M, Snoeck HW, Landau DA, Azizi E, Chan EM, Ciccia A, Gaublomme JT.   +26 more
europepmc   +1 more source

The Next Generation of Dashboards: a Spatial Online Analytical Processing (SOLAP) Platform for COVID-19. [PDF]

J Maps
Haynes D, Ahmadkhani M, Numainville J.
europepmc   +1 more source

Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, her2-negative breast cancer: a network meta-analysis. [PDF]

Front Immunol
Wu Y, Huang S, Wei Y, Huang M, Li C, Liang W, Qin T.   +6 more
europepmc   +1 more source

PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer. [PDF]

Mol Cancer
Liu C, Li J, Xu F, Chen L, Ni M, Wu J, Zhao H, Wu Y, Li J, Wu X, Chen X.   +10 more
europepmc   +1 more source

Transcription-replication conflicts underlie sensitivity to PARP inhibitors. [PDF]

Nature
Petropoulos M, Karamichali A, Rossetti GG, Freudenmann A, Iacovino LG, Dionellis VS, Sotiriou SK, Halazonetis TD.   +7 more
europepmc   +1 more source

Significance of homologous recombinant deficiency as a biomarker for drug sensitivity in colorectal cancer. [PDF]

Br J Cancer
Kato Y, Seishima R, Hattori K, Kato H, Ishida H, Shigeta K, Okabayashi K, Sugihara E, Takimoto T, Nakamura K, Nishihara H, Saya H, Kitagawa Y.   +12 more
europepmc   +1 more source

Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching. [PDF]

Protein Cell
Liu C, Xu F, Wu Y, Li J, Ni M, Xia S, Chen L, Zhao H, Yu M, Zhou Y, Zhang M, Li J, Wu X, Huang Y, Zhu T, Chen X.   +15 more
europepmc   +1 more source